Home Healthcare Medical Devices Cyclosporine Market

Cyclosporine Market Size, Share & Trends Analysis Report By Indication (Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye Disease, Other Indication), By Route of Administration (Oral, Parenteral) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: April 14, 2026 | Author: Dhanashri B | Format: | Report Code: SR7817DR | Pages: 160
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Cyclosporine Market Size Analysis
    1. Introduction
    2. Cyclosporine Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Transplant Rejection Prophylaxis
      2. Rheumatoid Arthritis
      3. Psoriasis
      4. Autoimmune Myasthenia Gravis
      5. Dry Eye Disease
      6. Other Indication
    3. Cyclosporine Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Parenteral
  7. North America Cyclosporine Market Size Analysis
    1. Introduction
    2. Cyclosporine Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Transplant Rejection Prophylaxis
      2. Rheumatoid Arthritis
      3. Psoriasis
      4. Autoimmune Myasthenia Gravis
      5. Dry Eye Disease
      6. Other Indication
    3. Cyclosporine Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Parenteral
    4. U.S.
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    5. Canada
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
  8. Europe Cyclosporine Market Size Analysis
    1. Introduction
    2. Cyclosporine Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Transplant Rejection Prophylaxis
      2. Rheumatoid Arthritis
      3. Psoriasis
      4. Autoimmune Myasthenia Gravis
      5. Dry Eye Disease
      6. Other Indication
    3. Cyclosporine Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Parenteral
    4. U.K.
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    5. Germany
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    6. France
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    7. Spain
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    8. Italy
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    9. Russia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    10. Nordic
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    11. Benelux
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    12. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
  9. APAC Cyclosporine Market Size Analysis
    1. Introduction
    2. Cyclosporine Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Transplant Rejection Prophylaxis
      2. Rheumatoid Arthritis
      3. Psoriasis
      4. Autoimmune Myasthenia Gravis
      5. Dry Eye Disease
      6. Other Indication
    3. Cyclosporine Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Parenteral
    4. China
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    5. Korea
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    6. Japan
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    7. India
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    8. Australia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    9. Taiwan
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    10. South East Asia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    11. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
  10. Middle East and Africa Cyclosporine Market Size Analysis
    1. Introduction
    2. Cyclosporine Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Transplant Rejection Prophylaxis
      2. Rheumatoid Arthritis
      3. Psoriasis
      4. Autoimmune Myasthenia Gravis
      5. Dry Eye Disease
      6. Other Indication
    3. Cyclosporine Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Parenteral
    4. UAE
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    5. Turkey
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    6. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    7. South Africa
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    8. Egypt
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    9. Nigeria
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    10. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
  11. LATAM Cyclosporine Market Size Analysis
    1. Introduction
    2. Cyclosporine Market Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
      1. Transplant Rejection Prophylaxis
      2. Rheumatoid Arthritis
      3. Psoriasis
      4. Autoimmune Myasthenia Gravis
      5. Dry Eye Disease
      6. Other Indication
    3. Cyclosporine Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Parenteral
    4. Brazil
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    5. Mexico
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    6. Argentina
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    7. Chile
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    8. Colombia
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
    9. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Indication 2022-2034 (USD MILLION/ Units)
        1. Transplant Rejection Prophylaxis
        2. Rheumatoid Arthritis
        3. Psoriasis
        4. Autoimmune Myasthenia Gravis
        5. Dry Eye Disease
        6. Other Indication
      3. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
  12. Competitive Landscape
    1. Cyclosporine Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. AbbVie Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Strides Pharma Science Limited
    3. Apotex Inc.
    4. EonLabs
    5. Mayne Pharma Group Limited
    6. Intas Pharmaceuticals Ltd.
    7. Novartis AG
    8. Santen Pharmaceutical Co., Ltd.
    9. Sun Pharmaceutical Industries Ltd.
    10. Teva Pharmaceutical Industries Ltd.
    11. Viatris Inc.
    12. Cipla Ltd.
    13. Reddy’s Laboratories Ltd.
    14. Glenmark Pharmaceuticals Ltd.
    15. Pfizer Inc.
    16. Astellas Pharma Inc.
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.